Emily Field

Stock Analyst at Barclays

(0.92)
# 3,856
Out of 5,182 analysts
15
Total ratings
25%
Success rate
-4.78%
Average return

Stocks Rated by Emily Field

Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $26.79
Upside: -6.68%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $110.23
Upside: +27.01%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $127.75
Upside: +21.33%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $868.27
Upside: +55.48%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $57.78
Upside: +29.80%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $180.67
Upside: +2.40%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $340.18
Upside: +2.89%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $197.38
Upside: +39.33%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $41.20
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $28.55
Upside: -
Upgrades: Equal-Weight
Price Target: n/a
Current: $54.22
Upside: -
Upgrades: Overweight
Price Target: n/a
Current: $783.74
Upside: -